“MTF Biologics works with Plastic and Reconstructive Surgeons to ensure that we are meeting their unique needs and the needs of their patients,” said Tom Shaffer, Executive Vice President, Global Sales & Marketing at MTF Biologics. “We are delighted to add Meso BioMatrix Surgical Mesh to the innovative tissues we provide. The clinicians with whom we work have been asking for a thinner, contourable, non-human tissue alternative that maintains its strength. Meso BioMatrix Surgical Mesh, which can be used in a range of procedures, is an ideal solution.”
Measuring only 0.3mm in thickness, Meso BioMatrix Surgical Mesh is an acellular porcine peritoneal biologic matrix designed to support soft tissue during cosmetic or soft tissue reconstruction procedures. The safe and natural scaffold allows for contour control, is easily suturable, and has exceptional strength. It supports cell integration and revascularization, and is available in a variety of clinically-relevant sizes ranging from 2×4 cm to 10×20 cm.
Meso Biomatrix Surgical Mesh is manufactured by DSM Biomedical and processed through the patented OPTRIX™ process, which removes potentially antigenic cells while preserving the natural extracellular matrix components such as proteins, glycosaminoglycans (GAGs) and growth factors.
MTF Biologics will feature Meso Biomatrix Surgical Mesh at the American Society of Plastic Surgeons’ Aesthetica Super Symposium in Las Vegas March 1-3, 2018, as well as the Dallas Cosmetic Surgery and Medicine Meeting and Dallas Rhinoplasty Meeting in Dallas February 28 – March 3, 2018.
About MTF Biologics
MTF Biologics, also known as the Musculoskeletal Transplant Foundation, is a nonprofit organization based in Edison, N.J. It is a consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions, and governed by a board of surgeons who are leading experts in tissue transplantation. As the world’s largest tissue bank, MTF Biologics saves and heals lives by honoring donated gifts, serving patients and advancing science. Since its inception in 1987, the organization has received tissue from more than 125,000 donors and distributed more than 8 million grafts for transplantation. Through its IIAM subsidiary, it has placed more than 55,000 non-transplantable organs for research. Through its Statline subsidiary, it has managed more than 10 million donor referrals. For more information, visit www.mtfbiologics.org.
SOURCE MTF Biologics